GeoVax Labs, Inc. (NASDAQ:GOVX) Short Interest Down 12.3% in March

GeoVax Labs, Inc. (NASDAQ:GOVX) was the target of a significant decrease in short interest in the month of March. As of March 15th, there was short interest totalling 610,600 shares, a decrease of 12.3% from the February 28th total of 696,400 shares. Based on an average daily volume of 678,200 shares, the days-to-cover ratio is presently 0.9 days. Currently, 6.9% of the company’s stock are short sold.

Institutional Investors Weigh In On GeoVax Labs

Several large investors have recently bought and sold shares of GOVX. Citadel Advisors LLC bought a new stake in shares of GeoVax Labs in the fourth quarter worth approximately $104,000. Virtu Financial LLC bought a new stake in GeoVax Labs in the 3rd quarter worth approximately $97,000. Geode Capital Management LLC raised its stake in GeoVax Labs by 59.0% during the 4th quarter. Geode Capital Management LLC now owns 90,139 shares of the company’s stock valued at $223,000 after buying an additional 33,440 shares during the last quarter. Finally, Northern Trust Corp purchased a new stake in GeoVax Labs during the 4th quarter valued at $29,000. 6.09% of the stock is currently owned by institutional investors.

GeoVax Labs Stock Down 7.6 %

Shares of NASDAQ GOVX traded down $0.09 during midday trading on Thursday, hitting $1.09. The stock had a trading volume of 163,639 shares, compared to its average volume of 607,203. The business’s 50 day moving average is $1.60 and its 200-day moving average is $2.09. GeoVax Labs has a 52 week low of $1.03 and a 52 week high of $11.18. The company has a market cap of $10.29 million, a P/E ratio of -0.19 and a beta of 3.06.

GeoVax Labs (NASDAQ:GOVX) last issued its earnings results on Thursday, March 27th. The company reported ($0.30) EPS for the quarter, beating the consensus estimate of ($0.79) by $0.49. The business had revenue of $3.00 million for the quarter, compared to analysts’ expectations of $2.38 million. As a group, analysts expect that GeoVax Labs will post -4.49 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, D. Boral Capital reiterated a “buy” rating and set a $18.00 target price on shares of GeoVax Labs in a report on Friday, March 28th. Five investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $14.20.

About GeoVax Labs

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.